Parkwood LLC Decreases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Parkwood LLC decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 0.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 261,595 shares of the company’s stock after selling 2,385 shares during the period. Novo Nordisk A/S comprises approximately 2.5% of Parkwood LLC’s holdings, making the stock its 4th largest position. Parkwood LLC’s holdings in Novo Nordisk A/S were worth $22,502,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. GQG Partners LLC raised its stake in shares of Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock worth $1,117,790,000 after buying an additional 5,556,460 shares during the period. Raymond James Financial Inc. purchased a new stake in Novo Nordisk A/S in the 4th quarter worth approximately $404,910,000. Loomis Sayles & Co. L P raised its stake in Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock worth $995,397,000 after acquiring an additional 2,947,771 shares during the period. Nuveen Asset Management LLC lifted its holdings in Novo Nordisk A/S by 73.2% during the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company’s stock valued at $537,189,000 after purchasing an additional 2,639,693 shares in the last quarter. Finally, Clearbridge Investments LLC boosted its position in shares of Novo Nordisk A/S by 59.8% in the fourth quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company’s stock worth $368,451,000 after purchasing an additional 1,602,549 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on NVO. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, April 28th. Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Dbs Bank lowered Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. Finally, BMO Capital Markets restated a “market perform” rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $135.00.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $65.38 on Wednesday. The firm has a market cap of $293.39 billion, a PE ratio of 19.87, a PEG ratio of 0.90 and a beta of 0.65. The stock has a 50 day moving average of $68.30 and a 200 day moving average of $85.37. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The firm had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $79.17 billion. On average, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.